HowardTrachtmanMD

Pediatric Nephrology • New York, NY

Professor of Pediatrics, NYU School of Medicine

Join to view full profile

Dr. Trachtman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Trachtman's full profile

Already have an account?

Office
403 E34th St
Room 1-02
New York, NY 10016
Phone+1 646-501-2663

Fax+1 212-263-4053
Is this information wrong?

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineFellowship, Pediatric Nephrology, 1981 - 1983
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1980 - 1983
Tufts Medical CenterResidency, Pediatrics, 1978 - 1980
Perelman School of Medicine at the University of PennsylvaniaClass of 1978

Certifications & Licensure

PA State Medical License 1992 - Present
NY State Medical License 1981 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Nephrology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2002-2003, 2005-2019
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Newsday - Top Doctors on Long Island Castle Connolly, 2008, 2010-2011
New York Magazine: Top Pediatricians Castle Connolly, 2003
Fellow (ASNF) American Society of Nephrology
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Start of enrollment: 2002 Mar 01
Completed
Phase 1
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) Start of enrollment: 2005 Jul 01
Completed
Phase 1
International Registry and Biorepository for TMA(Thrombotic Microangiopathy) Start of enrollment: 2007 Jan 01
Terminated
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Start of enrollment: 2008 Dec 01
Completed
Phase 2
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor Start of enrollment: 2008 Dec 01
Terminated
Phase 1
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients Start of enrollment: 2009 Nov 01
Completed
Phase 2, Phase 3
Nephrotic Syndrome Study Network Start of enrollment: 2010 Apr 01
Recruiting
Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant Start of enrollment: 2012 Jun 01
Completed
Phase 1
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 2
A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis Start of enrollment: 2013 Jul 01
Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker Start of enrollment: 2017 Dec 01
Completed
Join now to see all

Publications & Presentations

PubMed

Organic Pollutant Exposure and CKD: A Chronic Renal Insufficiency Cohort Pilot Study.
David M Charytan, Wenbo Wu, Mengling Liu, Zhong-Min Li, Kurunthachalam Kannan, Leonardo Trasande, Vineet Kumar Pal, Sunmi Lee, Howard Trachtman> ;Kidney Medicine. 2024 Mar 1
1 citations
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
Trachtman, H., Komers, R., Inrig, J.> ;Expert Review of Clinical Immunology. 2024 Feb 26
Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome.
Carboni, J., Thomas, E., Gipson, D., Brady, T., Srivastava, T., Selewski, D., Greenbaum, L., Wang, C., Dell, K., Kaskel, F., Massengill, S., Reidy, K., Tran, C., Trach...> ;Pediatric Nephrology. 2024 Feb 6
1 citations
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today.
Trachtman, H., Desmond, H., Williams, A., Mariani, L., Eddy, S., Ju, W., Barisoni, L., Ascani, H., Uhlmann, W., Spino, C., Holzman, L., Sedor, J., Gadegbeku, C., Subra...> ;Kidney International. 2024 Feb 1
Pediatric contributions and lessons learned from the NEPTUNE cohort study.
Zhai, Y., Desmond, H., Hao, W., Sethna, C., , Modi, Z., Yee, J., Sampson, M., Wang, C., Gipson, D., Trachtman, H., Kretzler, M.> ;Pediatric Nephrology. 2024 Jan 18
Bridging the 13-Year Evidence Gap: A Time for Age-Inclusive Research.
Louise Oni, Rona Smith, Alan D Salama, Jonathan Barratt, Howard Trachtman, Moin Saleem> ;Journal of the American Society of Nephrology. 2024 Apr 1
TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design.
Desmond, H., Choi, W., Manuel, R., Soleymanlou, N., Trachtman, H., Kretzler, M.> ;Kidney International Reports. 2023 Dec 1
FSGS Recurrence Collaboration: Report of a Symposium.
Debbie S Gipson, Chia-Shi Wang, Eloise Salmon, Rasheed Gbadegesin, Abhijit Naik, Simone Sanna-Cherchi, Alessia Fornoni, Matthias Kretzler, Sandra Merscher, Paul Hoover...> ;Glomerular Diseases. 2023 Nov 14
7 citations
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler, Dong-Wan Chae, Ulysses A Diva, Jürgen Floege, Loreto Gesualdo, Jula K Inrig, Don...> ;Lancet. 2023 Dec 2
1 citations
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Howard Trachtman, Ulysses Diva, Edward Murphy, Kaijun Wang, Jula Inrig, Radko Komers> ;Kidney International Reports. 2023 Oct 1
1 citations
The Significance of Hematuria in Podocytopathies.
Dorota Marchel, Howard Trachtman, Maria Larkina, Margaret Helmuth, Jennifer Y Lai Yee, Damian Fermin, Andrew S Bomback, Pietro A Canetta, Debbie S Gipson, Amy K Mottl,...> ;Clinical Journal of the American Society of Nephrology. 2023 Sep 21
1 citations
Kidney Considerations in Pediatric Obesity.
Alexandra Sawyer, Evan Zeitler, Howard Trachtman, Petter Bjornstad> ;Current Obesity Reports. 2023 Sep 1
Status of current trials and potential future trials with sparsentan.
Howard Trachtman, Radko Komers, Jula Inrig> ;Expert Opinion on Emerging Drugs. 2023 Dec 1
Developing an Edema Clinician-Reported Outcome Measure for Nephrotic Syndrome.
Debbie S Gipson, Maisha Pal, Hailey Desmond, Charles Anderson, Liron Walsh, Howard Trachtman, Susan F Massengill, Patrick Gipson, Panduranga S Rao, Joshua Thurman, Jef...> ;Glomerular Diseases. 2023 Jun 12
The association of low birthweight and prematurity on outcomes in children and adults with nephrotic syndrome-a NEPTUNE cohort study.
Sangeeta Hingorani, Keisha L Gibson, Yuping Xie, Yujie Wang, Sean Eddy, John Hartman, Matthew Sampson, Clarissa Cassol, David Thomas, Debbie S Gipson, Howard Trachtman...> ;Pediatric Nephrology. 2023 Oct 1
11 citations
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J L Heerspink, Alex Mercer, Irene L Noronha, Ja...> ;Kidney International Reports. 2023 May 1
35 citations
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Hiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, Jonathan Barratt, Stewart Bieler, Ulysses Diva, Jula Inrig, Radko Komers, Alex Mercer, Irene L Noronha, Miche...> ;Lancet. 2023 May 13
11 citations
Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.
Laura H Mariani, Sean Eddy, Fadhl M AlAkwaa, Phillip J McCown, Jennifer L Harder, Viji Nair, Felix Eichinger, Sebastian Martini, Adebowale D Ademola, Vincent Boima, He...> ;Kidney International. 2023 Mar 1
2 citations
Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes.
Mahmoud Kallash, Yujie Wang, Abigail Smith, Howard Trachtman, Rasheed Gbadegesin, Carla Nester, Pietro Canetta, Chen Wang, Tracy E Hunley, C John Sperati, David Selews...> ;Clinical Journal of the American Society of Nephrology. 2023 Mar 1
36 citations
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.
Agnes Trautmann, Olivia Boyer, Elisabeth Hodson, Arvind Bagga, Debbie S Gipson, Susan Samuel, Jack Wetzels, Khalid Alhasan, Sushmita Banerjee, Rajendra Bhimma, Melvin ...> ;Pediatric Nephrology. 2023 Mar 1
2 citations
Maximizing the value of the open label extension phase of randomized clinical trials.
Howard Trachtman, Rosanna Coppo, Moin Saleem, Alex Mercer, Radko Komers> ;Journal of Nephrology. 2023 Jul 1
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.
Griffin, S., Geletka, R., Wong, M., Campbell, K., Trachtman, H.> ;International Journal of Nephrology and Renovascular Disease. 2023 Jan 1
4 citations
Use of patient portals to support recruitment into clinical trials and health research studies: results from studies using MyChart at one academic institution.
Scott E Sherman, Aisha T Langford, Joshua Chodosh, Carina Hampp, Howard Trachtman> ;JAMIA Open. 2022 Dec 1
10 citations
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Carla Nester, Gerald B Appel, Andrew S Bomback, Koenraad Peter Bouman, H Terence Cook, Erica Daina, Bradley P Dixon, Kara Rice, Nader Najafian, James Hui, Steven D Pod...> ;American Journal of Nephrology. 2022 Jan 1
5 citations
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Dan...
Steven D Podos, Howard Trachtman, Gerald B Appel, Andrew S Bomback, Bradley P Dixon, Jack F M Wetzels, H Terence Cook, Samir V Parikh, Matthew C Pickering, James Tumli...> ;American Journal of Nephrology. 2022 Jan 1
Join now to see all

Journal Articles

Does What Goes Around Always Come Around?
Howard Trachtman, MD, Journal of the American Society of Nephrology
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Howard Trachtman, Peter Nelson, Abanti Chaudhuri, Jai Radhakrishnan, Olga Zhdanova, Debbie S Gipson, Tarak Srivastava, Kenneth Lieberman, Vimal Kumar Derebail, Jonatha..., Journal of the American Society of Nephrology

Press Mentions

Tonsillectomy for the Management of Immunoglobulin A NephropathyMay 3rd, 2019
Experimental Drug More Effective in Treating Rare Kidney DiseaseOctober 26th, 2018
Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of NephrologyOctober 25th, 2018
Join now to see all